EU panels backs approval of Ariad's Iclusig for leukemia

03/25/2013 | American City Business Journals

Ariad Pharmaceuticals' Iclusig, or ponatinib, was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use as a treatment for chronic, accelerated or blast-phase chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Global Medical Safety Director - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Compliance Manager/Sr. Compliance Manager- Auditing
Genentech
South San Francisco, CA
Director of Program Development
AdvaMed
Washington DC, DC
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC